MSH|^~\&|LAB|RCH|||201911141441||ORU^R01|4105754|D|2.3|||AL|NE PID|1||RC00007229|RC7037|LABTEST^ALMONDTHINS^||20130120|F||||||||||RC000622/19|9875495454 OBR|1|35155^LAB|00026997^1311:C00024R^LAB^131119:C24^35155|522.2490^BHCG^Beta-HCG^^^21198-7||201911131243|201911131000|||||||201911131243||||||||||LAB|F|||| NTE|1||>dCG5 limit OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|349466^^Y|IU/L|<10|H||A^S|F|||201911141441 NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L): NTE|2|| NTE|3||Male or non-pregnant female Less than 10 NTE|4||Pregnant female: NTE|5||Time after LMP: Expected beta-HCG range(WHO 3rd IRP): NTE|6||4th week 25 - 426 NTE|7||5th week 25 - 7340 NTE|8||6th week 1080 - 56500 NTE|9||10th week 54100 - 288000 NTE|10||18th week 8910 - 66000 NTE|11||31st week 5310 - 27400 NTE|12||*************************NOTE******************************* NTE|13||Occasional patients with heterophile antibodies may have NTE|14||erroneous BHCG results. Serum BHCG should not be used for NTE|15||routine pregnancy tests. Urine does not contain heterophile NTE|16||antibodies and may be used where apparent discrepant results NTE|17||are experienced. NTE|18||Method:Beckman Access/DxI